Evaluation of different subcellular fractions of Vibrio cholerae O139 in protection to challenge in experimental cholera

FEMS Immunology and Medical Microbiology

Volumn 19, Issue 4, 1997, Pages 323-329

  Bondre, Vijay P ^a   Sinha, V B ^a   Srivastava, Brahm S ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Immunization; Protection; Subcellular fraction; Vibrio cholerae O139

Indexed keywords

CHOLERA TOXIN; CHOLERA VACCINE; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLERA; CONTROLLED STUDY; CROSS REACTION; ILEUM; IMMUNIZATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VIBRIO CHOLERAE;

ANIMALS; BACTERIAL OUTER MEMBRANE PROTEINS; BACTERIAL PROTEINS; BLOTTING, WESTERN; CELL FRACTIONATION; CELL MEMBRANE; CHOLERA; CHOLERA TOXIN; CHOLERA VACCINES; ILEUM; LIPOPOLYSACCHARIDES; POLYSACCHARIDES, BACTERIAL; RABBITS; VACCINES, SYNTHETIC; VIBRIO CHOLERAE;

EID: 0031456531     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-8244(97)00099-0     Document Type: Article

References (29)

1. Morris, J.G. (1990) Non-O group 1 Vibrio cholerae: a look at the epidemiology of an occasional pathogen. Epidemiol. Rev. 12, 179-191.
2. Ramamurthy. T., Garg, S., Sharma, R., Bhattacharya, S.K., Nair, G.B., Shimada, T., Takeda, T., Karasawa, T., Kurazano, H., Pal, A. and Takeda, Y. (1993) Emergence of novel strain of Vibrio cholerae with epidemic potential in southern and eastern India. Lancet 341, 703-704.
3. Albert, M.J., Siddique, A.K., Islam, M.S., Faruque, A.S.G., Ansaruzzaman, M., Faruque, S.M. and Sack, R.B. (1993) Large outbreak of clinical cholera due to Vibrio cholerae non-O1 in Bangladesh. Lancet 341, 704.
4. Cholera Working Group, International Centre for Diarrheal Diseases Research, Bangladesh (1993) Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 342, 387-390.
5. Calia, K.E., Murtogh, M., Ferraro, M.J. and Calderwood, S.B. (1994) Comparison of Vibrio cholerae O139 with V. cholerae O1 classical and El Tor biotypes. Infect. Immun. 62, 1504-1506.
6. Waldor, M.K., Colwell, R. and Mekalanos, J.J. (1994) The Vibrio cholerae O139 serogroup antigen includes an O-antigen capsule and lipopolysaccharide virulence determinants. Proc. Natl. Acad. Sci. USA 91, 11388-11392.
7. Das, B., Ghosh, R.K., Sharma, C., Vasin, N. and Ghosh, A. (1993) Tandem repeats of cholera toxin gene in Vibrio cholerae O139. Lancet 342, 1173-1174.
8. Swerdlow, D. and Ries, A.A. (1993) Vibrio cholerae non O1 - the eighth pandemic? Lancet 342, 382-383.
9. Hall, R.H., Khambaty, F.M., Kothary, M.H., Keasler, S.P. and Tall, B.D. (1994) Vibrio cholerae non-O1 serogroup associated with cholera gravis genetically and physiologically resembles O1 El Tor cholera strains. Infect. Immun. 62, 3859-3863.
10. Higa, N., Honma, Y., Albert, M.J. and Iwanaga, M. (1993) Characterization of Vibrio cholerae O139 synonym Bengal isolated from patients with cholera-like disease in Bangladesh. Microbiol. Immunol. 37, 971-974.
11. Johnson, J.A., Salles, C.A., Panigrahi, P., Albert, M.J., Wright, A.C., Johnson, R.J. and Morris Jr., J.G. (1994) Vibrio cholerae O139 synonym Bengal is closely related to V. cholerae El Tor but has important differences. Infect. Immun. 62, 2108-2110.
12. Waldor, M.K. and Mekalanos, J.J. (1994) ToxR regulates virulence gene expression in non-O1 strains of Vibrio cholerae that cause epidemic cholera. Infect. Immun. 62, 72-78.
13. Jacob, A., Sinha, V.B., Sahib, M.K., Srivastava, R., Kaper, J.B. and Srivastava, B.S. (1993) Identification of 33 kDa antigen associated with an adhesive and colonizing strain of Vibrio cholerae El Tor and its role in protection. Vaccine 11, 376-381.
14. Singh, S.N., Srivastava, R., Sinha, V.B. and Srivastava, B.S. (1994) A 53 kDa protein of Vibrio cholerae strain O395 involved in intestinal colonization. Microb. Pathog. 17, 69-78.
15. Sengupta, D.K., Boesman-Finkelstein, M. and Finkelstein, R.A. (1996) Antibody against the capsule of Vibrio cholerae O139 protects against experimental challenge. Infect. Immun. 64, 343-345.
16. Westphal, O. and Jann, K. (1965) Bacterial lipopolysaccharides. Extraction with phenol-water and further applications of the procedure. Methods Carbohydr. Chem. 5, 83-91.
17. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J. (1951) Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
18. Dubois, M., Gilles, K.A., Hamilton, J.K., Rebers, P.A. and Smith, F. (1956) Colorimetric method for determination of sugars and related substances. Anal. Chem. 28, 350-356.
19. Tsai, C.M. and Frasch, C.E. (1982) A sensitive silver stain for detecting lipopolysaccharides in polyacrylamide gels. Anal. Biochem. 119, 115-119.
20. Dubray, G. and Bezard, G. (1982) A highly sensitive periodic acid-silver stain for 1,2-diol groups of glycoproteins and polysaccharides in polyacrylamide gels. Anal. Biochem. 119, 325-329.
21. Harlow, E. and Lane, D. (1988) Antibodies. In: Molecular Cloning: A Laboratory Manual, pp. 283-612. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
22. De, S.N. and Chatterjee, D.N. (1953) An experimental study of the mechanism of action of Vibrio cholerae on the intestinal mucous membrane. J. Pathol. Bacteriol. 66, 559-562.
23. Finkelstein, R.A. (1962) Vibriocidal antibody inhibition analysis: a technique for the identification of the predominant vibriocidal antibodies in serum and for the recognition and identification of Vibrio cholerae antigens. J. Immunol. 89, 264-271.
24. Svennerholm, A.-M. and Holmgren, J. (1976) Synergistic protective effect in rabbits of immunisation with Vibrio cholerae lipopolysaccharide and toxin/toxoid. Infect. Immun. 41, 237-243.
25. Jonson, G., Osek, J., Svennerholm, A.-M. and Holmgren, J. (1996) Immune mechanism and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development. Infect. Immun. 64, 3778-3785.
26. Tacket, C.O., Morris Jr., J.G., Losonasky, G.A. et al. (1994) Volunteer studies investigating the pathogenicity of Vibrio cholerae O139 and the protective efficacy conferred by both primary infection and by vaccine strain CVD 112. In: Proceedings of the 30th Joint Conference, U.S. Japan Co-operative Medical Science Program, Cholera and Related Diarrheal Diseases, pp. 142-147.
27. Wyle, F.A., Artenstein, M.S., Brandt, B.L., Tramont, E.C., Kasper, D.L., Altieri, P.L., Berman, S.L. and Lowenthal, J.P. (1972) Immunologic response of man to Group B meningococcal polysaccharide vaccines. J. Infect. Dis. 126, 514-522.
28. Robbins, J.B. and Schneerson, R. (1990) Polysaccharide- protein conjugates: a new generation of vaccines. J. Infect. Dis. 161, 821-832.
29. Bondre, V.P., Srivastava, R., Sinha, V.B. and Srivastava, B.S. (1997) Screening of TnphoA mutants of Vibrio cholerae O139 for identification of antigens involved in colonisation. J. Med. Microbiol. 46, 1-5.